Andere talen AdAlta Limited

Aandelen

Beurs gesloten - Australian S.E. Andere beurzen 08:10:47 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,023 ^AUD	0,00%		-14,81%	-4,17%

08/04	AdAlta verkent kankerimmunotherapie joint venture voor westerse markt	MT
26/02	AdAlta Limited rapporteert resultaten voor het halfjaar dat eindigde op 31 december 2023	CI

AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	29/04
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	08/04
AdAlta delivers positive Phase I Extension Study results for AD-214	08/03
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02
AdAlta-La Trobe University Collab Discovers New i-Bodies for Malaria Treatment; Shares Climb 4%	19/12
Adalta Posts Upbeat Results from Phase I Trial of Fibrotic Disease Drug	22/11
AdAlta closes oversubscribed $1.65 million raise	08/11
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9%	07/11
AdAlta to Seeks AU$1.2 Million from Share Placement	03/11
AdAlta making material progress on partnering talks	23-10-23
AdAlta Receives AU$2.4 Million R&D Tax Rebate	18-10-23
AdAlta says new AD-214 dosing models enhance partnering potential	26-09-23
AdAlta completes enrolment for AD-214 fibrosis safety trial	21-09-23
Adalta Completes Enrollment for Phase 1 Study on Fibrotic Disease Medication; Shares Fall 9%	20-09-23
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25-08-23
AdAlta to Present at August 24th Virtual Investor Summit	16-08-23
AdAlta back in the clinic with AD-214	07-08-23
Adalta Carries Out First Dosing in Phase One Extension Study of Fibrotic Disease Medication; Shares Jump 4%	04-08-23
AdAlta eyes AD-214 Phase I extension study	18-07-23
AdAlta Raises AU$1.9 Million Via Oversubscribed Shortfall Facility	13-07-23

Geen resultaten voor deze zoekopdracht